No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 26 of the 30 quarters in the window, leaving 4 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 31
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for NextCure, Inc. (NXTC) stock was $5.64 as of Oct 6, 2026, 3:28 PM EDT, up 11.68% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -13.5% · 3-year avg -30.6%/yr · 5-year avg -44.3%/yr
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies.
Biotechnology · Beltsville, MD
Next Earnings Date
Nov 4, 2026
29 days away
EPS Estimate
-0.90
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.85
vs Estimate
$-1.92
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1NXTC | $20.37M | $5.64 | +11.68% | -13.47% | -44.29% | N/A | N/A |
| 2QNTM | $20.22M | $3.16 | -3.36% | -82.13% | -49.16% | N/A | vs NXTC |
| 3ACTU | $19.16M | $0.80 | -8.46% | -87.34% | N/A | N/A | vs NXTC |
| 4AYTU | $21.90M | $2.04 | N/A | -6.80% | -48.14% | -68.87% | vs NXTC |
| 5NEUP | $18.70M | $3.46 | +0.29% | -82.12% | N/A | N/A | vs NXTC |
| 6PIII | $18.67M | $5.70 | -7.62% | -28.56% | -58.41% | N/A | vs NXTC |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$20.00
+254.6% upside
Low
$20.00
Current
$5.64
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.90 | $-0.90 | $-0.90 | 1 |
| Quarter ending Dec 2026 | $-0.79 | $-0.79 | $-0.79 | 1 |
| Quarter ending Mar 2027 | $-2.13 | $-2.13 | $-2.13 | 1 |
| Quarter ending Jun 2027 | $-2.21 | $-2.21 | $-2.21 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-6.52 | $-6.34 | $-6.18 | 1 |
| FY 2027 | $-1.38 | $-1.38 | $-1.38 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.30M | $3.30M | $3.30M | 2 |
| FY 2027 | $7.00M | $7.00M | $7.00M | 2 |
